Target intelligence / Profile preview

Toll-like receptor 4 MyD88-dependent pathway (TLR4 MyD88-dependent pathway)

Target
TLR4 MyD88-dependent pathway
Molecular classification
Receptor (for TLR4), Adaptor protein (for MyD88), Signal transduction pathway, Pattern recognition receptor pathway
01

Overview

The Toll-like receptor 4 MyD88-dependent pathway is a canonical signaling cascade activated upon recognition of microbial components such as lipopolysaccharide (LPS) by Toll-like receptor 4 (TLR4) on immune and other cells. Engagement of TLR4 leads to recruitment of the adaptor protein MyD88 through the TIR (Toll/interleukin-1 receptor) domain. MyD88 then assembles with IRAK kinases to form the active “Myddosome,” resulting in downstream phosphorylation events and activation of transcription factors NF-κB and AP-1. This signaling pathway drives production of pro-inflammatory cytokines and is central to innate immune responses, but is also implicated in chronic inflammation, infection susceptibility, and diseases such as sepsis and autoimmune disorders

Other names
TLR4-MyD88 pathwayToll-like receptor 4 signaling (MyD88-dependent)TLR4 signaling pathway (canonical/MyD88)Canonical TLR4 pathway (MyD88-dependent)
02

Mechanism of action

Antagonism or inhibition of TLR4 to block signal initiation Inhibition of MyD88 recruitment or function to prevent downstream signaling Inhibition of IRAK kinases, TRAF6, or other downstream effectors to block signal propagation

03

Biological functions

Immune responseSignal transductionInflammationCytokine productionCell activation (especially in immune and endothelial cells)
04

Disease associations

InflammationInfectionCancerCardiovascular diseaseAutoimmune diseaseNeurodegenerative diseaseSepsis
05

Safety considerations

Systemic immunosuppression (increased risk of infection)Potential impairment of pathogen clearanceCytokine release syndrome if pathway is aberrantly activated
06

Interacting drugs

Eritoran (a TLR4 antagonist)

2 more in the full profile.

07

Biomarkers

Increased expression of TLR4 or MyD88 in patient immune cellsLevels of pro-inflammatory cytokines (e.g., IL-6, TNF-α)Genetic variants in TLR4 or MYD88 associated with susceptibility to inflammation or infection

Beyond the preview

Go deeper on Toll-like receptor 4 MyD88-dependent pathway (TLR4 MyD88-dependent pathway).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toll-like receptor 4 MyD88-dependent pathway (TLR4 MyD88-dependent pathway).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call